You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: INOVODEL, INC.            Topic: NHLBI

    SUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Pigment Sensing Pulse Oximeter Technology for Mitigating Racial Bias in Oxygen Saturation Measurements

    SBC: PENDERIA TECHNOLOGIES, INC.            Topic: 100

    Abstract Wearable pulse oximetry sensors are among the most ubiquitous medical technologies used in healthcare. Clinicians rely on pulse oximeters to monitor patient health during disease states and medical procedures. However, numerous studies have shown this technology to be racially biased; hypoxemia is three times more likely to go undetected in patients with dark skin compared to those with l ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Agents Targeting Cryptococcal Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Cryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Treatment for Alcohol-associated Liver Disease

    SBC: MITOTHERAPEUTIX, LLC            Topic: 350

    Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of preventable morbidity and mortality. In the U.S., alcohol abuse impacts over 10 million individuals ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers

    SBC: BORROW MY GLASSES LLC            Topic: NIA

    1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Making Mindfulness-Based Cognitive Therapy accessible for underserved pregnant people: Developing Center M for commercialization

    SBC: CENTER MOM, INC.            Topic: 104

    PROJECT SUMMARY/ABSTRACT A highly effective intervention to prevent perinatal depression, mindfulness-based cognitive therapy for perinatal depression (MBCT), exists; however, critical implementation gaps prevent its wide use. And though universally recommended, not all prenatal care clinics effectively screen for perinatal depression (PD). Overcoming current implementation gaps is imperative to a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels

    SBC: Gamma Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT g' (pronounced "gamma prime") fibrinogen (GPF) is an alternative splice isoform of the blood coagulation factor fibrinogen. This fibrinogen variant contains a high affinity binding site for the coagulation factor thrombin that localizes thrombin on the growing blood clot. Thrombin binds to GPF via thrombin's heparin binding site. This allows thrombin to continue forming th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government